For Immediate Release
Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes
Contact: Kathryn Ryan
914-740-2250
kryan@liebertpub.com
New Rochelle, NY, March 7, 2024—The U.S. Food and Drug Administration has approved a higher dose of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide for individuals with a body mass index greater than 27 kg/m2. A new study, which evaluated how effective the real-world use of semaglutide (Ozempic® or Wegovy®) is in overweight or obese patients with type 1 diabetes, is published in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT). Click here to read the article now.
Fifty overweight or obese patients with type 1 diabetes (T1D) were started on semaglutide and followed for one year. They were compared with 50 computer-matched control patients who were not on any weight loss medications during the same period. The investigators reported significantly greater declines in mean body mass index (BMI), body weight, and HbA1c, and increase in continuous glucose monitoring (CGM) time- in- range (TIR) in the semaglutide group compared to the control group, with no difference in insulin dose changes, time above range, or time below range.
Satish Garg, MD, from the University of Colorado Denver, and Editor-in-Chief of Diabetes Technology & Therapeutics, and coauthors, concluded the following: “We strongly recommend performing prospective, large, randomized clinical trials with newer GLP-analogs like semaglutide and tirzepatide (twin-cretin) for subjects with T1D associated with overweight and/or obesity for safe use.”
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, University of Colorado Denver, Barbara Davis Center for Diabetes, the Journal covers breakthrough technologies and new therapeutic drug classes, behavioral aspects and approaches to diabetes care, and the latest advancements and applications of new and emerging technologies including continuous glucose monitoring, alternate insulin delivery methods, artificial pancreas, telemedicine and computerized case management, new insulins with ultra-rapid onset of action, and detection and prevention of hypoglycemia. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).
About the Publisher
Mary Ann Liebert, Inc.is a global media company dedicated to creating, curating, and delivering impactful peer-reviewed research and authoritative content services to advance the fields of biotechnology and the life sciences, specialized clinical medicine, and public health and policy. For complete information, please visit the Mary Ann Liebert, Inc. website.